Today, the 11th Annual Meeting of CSSCR officially commenced at the Guangzhou Yuexiu International Congress Center. The conference invited leading scientists in the field of stem cells in China to give keynote speeches, with exciting sub-sessions covering cutting-edge areas of stem cell research and regenerative medicine.

Tomorrow, Prof. ZHAO Bing, Chief Scientist of bioGenous and Professor at Fudan University, will deliver a special presentation titled "Organoid Models for Infectious Diseases and Developmental Defects" at the "Stem Cell Modeling Development and Disease" session. At the same time, bioGenous will be at Booth 51, welcoming scholars and experts to engage in discussions on key scientific issues in the field of organoid research.

▼

On the first day of the conference, there was a bustling crowd at the bioGenous booth. Many professionals and experts expressed a strong desire for collaboration, impressed by the company’s over ten years of technical accumulation and unique insights in the field of organoids.

We look forward to welcoming scholars and experts to the bioGenous booth, where there will also be a lucky draw with the chance to win custom notebooks, Lock&Lock water bottles, notepads, and adorable canvas bags!

bioGenous Reagents Display/Lucky Draw Prizes▼

/ Conference Brief Agenda /

About bioGenous

bioGenous is a leading one-stop provider of organoid technology products and solutions. The company has been deeply involved in basic organoid research and translational applications for many years. Since 2016, bioGenous has gradually established and perfected a full range of upstream organoid technologies, covering multiple tissue and tumor organoid culture, development and disease modeling, genetic manipulation, efficacy and toxicity evaluation, animal transplantation, multiomics atlas of organoids, organoid precision medicine, automated operations, and more. In 2020, to meet the explosive global demand for CDMO services in organoid technology, bioGenous built a 2,000-square-meter production facility that complies with international GMP standards for biopharmaceuticals. The company is committed to creating a standardized and modular CDMO service platform for basic biological and medical research, drug development, and precision medicine, leading a revolution in biomedical models and advancing human health.